Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.

TMZ is the only drug that has improved survival of GBM patients although minimally. However, a number of GBM patients did not respond to TMZ-based chemotherapy. Here, we found that miR-505 inhibited tumorigenesis as a tumor suppressor in glioblastoma. In addition, TMZ could increase the levels of miR-505 and combination with pri-miR-505 and TMZ promoted the suppressive role mediated by miR-505 in GBM cells. Furthermore, miR-505 inactivated the Wnt/β-catenin signaling pathway by directly targeting and inhibiting WNT7B. In conclusion, our results demonstrated that the induction of miR-505 in combination with TMZ treatment could be a useful therapeutic strategy for suppressing GBM.